Regulation of B-Cell Activation by Complement Receptors CD21 and CD35

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|9|23|1849-1860

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.9, Iss.23, 2003-09, pp. : 1849-1860

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting CD44 in mast cell regulation

By Tanaka Satoshi  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 1, 2010-01 ,pp. : 31-43

Informa Healthcare

Access to resources Recommend Favorite

C4- and CD21/CD35-deficiency predisposes mice to spontaneous autoreactivity

By Pozdnyakova O.O.   Paul E.   Schneider T.J.   Carroll M.C.  

Immunopharmacology, Vol. 49, Iss. 1, 2000-08 ,pp. : 79-79

Elsevier

Access to resources Recommend Favorite

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

By Bornstein Gadi   Quéva Christophe   Tabrizi Mohammad   Abbema Anne   Chavez Carlos   Wang Ping   Foord Orit   Ahluwalia Kiran   Laing Naomi   Raja Sandhya   Wen Shenghua   Green Larry   Yang Xiaodong   Webster Carl   Stewart Ross   Blakey David  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 561-574

Springer Publishing Company

Access to resources Recommend Favorite

Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art

By  

Current Drug Targets, Vol. 17, Iss. 9, 2016-07 ,pp. : 1072-1082

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells

By  

Current Gene Therapy, Vol. 14, Iss. 1, 2014-02 ,pp. : 35-43

Bentham Science Publishers

Access to resources Recommend Favorite